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Abstract
In the present study, we investigated the effects of noscapine (0.5-2 µM), an alkaloid from 
the opium poppy (Papaver somniferum), on primary murine cortical neurons exposed to 60 
min oxygen–glucose deprivation (OGD) in the presence of 5 µM BD-1047, a selective sigma-1 
receptor antagonist. The experiments were performed on cortical neurons after 11–16 days of 
culture. To initiate oxygen–glucose deprivation, the culture medium was transferred to glucose-
free DMEM, and placed in a humidified incubation chamber containing a mixture of 95% N2 and 
5% CO2 at 37 °C for 60 min. In order to explore the effect on neurons under oxygen–glucose 
deprivation in this condition, some cultures were pretreated with noscapine and BD1047 together, 
24 h prior to OGD followed by 24 h recovery. Cell viability, nitric oxide (NO) production and 
intracellular calcium concentration ([Ca2+]i) levels were evaluated by MTT assay, the modified 
Griess method, and Fura-2, respectively. Pretreatment of the cultures with noscapine in the 
presence of BD1047 significantly increased cell viability and decreased NO generation in a dose-
dependent manner compared to BD1047 alone. Pretreatment with 2 μM noscapine and BD-1047 
was shown to decrease the rise in [Ca2+]i induced by sodium azide (NaN3) and glucose deprivation. 
We concluded that noscapine in the presence of BD1047 could protect primary cortical neurons 
after oxygen–glucose deprivation-induced cell injury but this effect was not complete. Our results 
indicate that neuroprotective effects of noscapine could be mediated partially through activation 
of sigma-1 receptor and by decreasing NO production and [Ca2+]i levels. 
 
Keywords: Noscapine; NO; Oxygen-glucose deprivation; Cortical culture; Sigma receptor; 
Intracellular calcium.
Introduction
Excitotoxicity and excessive intracellular 
calcium play central roles in causing 
neurodegenerative disease such as stroke and 
traumatic brain injury, amyotrophic lateral 
sclerosis, Alzheimer’s disease, and Parkinson’s 
disease (1, 2). Although in excitotoxicity 
process, glutamate has an important role in 
cerebral injury subsequent to stroke, sigma 
receptor agonists are also effective in reducing 
in-vitro ischemic process by diminishing the 
glutamate release and blocking the excessive 
intracellular calcium (2–4).
Initially it was believed that the sigma 
receptors were a subtype of opioid receptor; 
however, further studies have shown that these 
receptors are different, independent classes of 
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proteins and have a distinct pharmacological 
profile consisting of two subtypes termed 
sigma-1 and sigma-2 (5–8). Both subtypes of 
receptors are widely distributed in different 
parts of the CNS, e.g. prefrontal cortex, 
hippocampus, striatum, and several other 
tissues, including the immune and endocrine 
systems (2, 6 and 9).
 These receptors have many physiological 
and pathophysiological roles in learning and 
memory, movement disorders, drug addiction, 
amnesia, pain, depression, Alzheimer’s 
disease, stroke, retinal neuroprotection, HIV 
infection, and cancer. So, they are candidate 
as a therapeutic target for various diseases 
(3, 10). In this context, especially sigma-1 
receptors have an important role in modul-
ating several physiological event such as 
the regulation of inositol 1,4,5-triphosphate 
receptors and calcium mobilization from 
endoplasmic reticulum stores, modulation 
of calcium entry through ion channels at the 
plasma membrane including Kv1.4 channels, 
N-methyl-d-aspartate (NMDA) receptors, and 
voltage-dependent calcium channels. Simi-
larly, in in-vitro and in-vivo studies, sigma-1 
receptor activation inhibited ischemic injury 
by decreasing NO production via suppressing 
such as decrease glutamate and NMDA-
induced nitric oxide synthase (NOS) activation. 
Therefore, the sigma-1 receptor could be a 
novel target in treatment of many diseases 
such as stroke (6, 11–14). For example, it has 
been shown that activation of sigma-1 receptor 
agonists has protective effect in focal cerebral 
ischemia injury by suppression neuronal NO 
production (11). Also, Katnik et al. (3) have 
shown that regulating intracellular calcium 
by activation of sigma receptors in cortical 
neurons exposed to ischemia is one of the 
mechanisms by which these receptors may 
possibly exert their neuroprotective properties 
in this condition. They also demonstrated 
that the sigma-1 receptor antagonist, BD1047 
blocked this neuroprotective effect.
Noscapine is a benzylisoquinoline alkaloid 
from the opium poppy Papaver somniferum 
and unlike many other alkaloids from the opium 
latex does not have any notable secondary 
sedative, hypnotic, analgesic, or euphoric 
properties (15–17). Ye et al. (18) showed that 
noscapine could inhibit murine lymphoid 
tumors, probably by suppressing microtubules 
assembly. Also, this agent could cause cell 
cycle arrest in several human and murine 
neoplasms including lymphoma, thymoma, 
melanoma, and breast cancer and induced 
apoptosis in both in-vitro and in-vivo study 
(15, 19). Kamei (20) showed that pretreatment 
with rimcazole, a specific antagonist of 
sigma-receptors decreased antitussive effects 
of noscapine considerably. Ebrahimi (21) 
showed that the effect of noscapine on cough 
suppression was probably via interference 
with the actions of bradykinin. In addition, 
Mahmoudian et al. (22) demonstrated that 
noscapine decreased inflammatory damage 
during ischemia in rat pups model of ischemic 
brain injury. Khanmoradi et al. (23) showed that 
Noscapine protected renal tissue in Wistar rats 
against ischemia-reperfusion injury by down 
regulation of the inflammatory mediators. 
Another study in our lab demonstrated that 
noscapine significantly increased neuronal 
cell viability after oxygen-glucose deprivation 
for 30, 60, and 240 min in murine primary 
cortical culture probably by re-establishment 
of calcium homeostasis following a decrease 
in NO production (24).
In this work, we aim to determine whether 
sigma receptors are involved in protective 
effects of noscapine after oxygen–glucose 
deprivation/recovery (OGD/R). In addition, 
we want to show if the protective effects of 
noscapine are dependent on modulation of 
intracellular calcium and/or NO production.
Experimental
Preparation of primary cell cultures
Timed pregnant mouse was purchased from 
Iran University of medical science. Under 
anaesthesia using chloroform, the pregnant 
mouse was killed by cervical dislocation and 
mouse embryos (E15–18) were euthanized and 
decapitated. Fetal cerebral cortex was used 
for primary mice cortical neuron isolation and 
cultured as described previously (25, 26).
The resulting homogenate was then 
centrifuged at 300 ×g for 5 min at 20 °C and 
were seeded in 12-well plates (at a density 
of 6 × 104) and glass coverslips pre-treated 
with poly-D-lysine (10 µg/mL; Sigma–
Aldrich) for viability evaluation via OGD 
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and chemical OGD, respectively. The cultures 
were maintained at 37 °C in 100% humidity 
and in a 95% air and 5% CO2 atmosphere. 
The plating medium consisted of RPMI-
1640 supplemented with 10% FBS, 5% horse 
serum, and 100 IU/mL penicillin and100 
µg/ml streptomycin (Sigma-Aldrich, Saint 
Louis, MS, USA). 
After 24–48 h, to eliminate the very small 
number of non-neuronal cells, 10 µM cytosine 
arabinoside (Sigma, St. Louis, MO, USA) 
was added to medium culture for 3 days. The 
experiments were performed after 11-16 
days in-vitro. All experiments were carried 
out by the Institute of Animal Care Committee 
at Iran University of Medical Sciences.
Oxygen–glucose deprivation and drug 
exposure
After 11-16 days in culture, noscapine was 
exposed to Oxygen–glucose deprivation as 
described previously (27).
The cells were exposed with 5 µM 
BD1047, the selective sigma-1 antagonist 
(Sigma-Aldrich, St. Louis, MO, USA) with or 
without 0.5-2 µM noscapine (Sigma-Aldrich, 
St. Louis, MO, USA), 24 h before OGD. The 
current concentration of noscapine was chosen 
according to our previous research works.
Briefly, to achieve OGD, the cells were 
treated to OGD medium containing glucose/
glutamine-free DMEM without FBS and 
transferred in an anaerobic chamber with 95% 
(v/v) N2 and 5% (v/v) CO2. The anaerobic 
chamber was kept sealed at 37 °C. After 
60 min in OGD, the chamber was opened 
and the cultures were removed from the 
anaerobic chamber and returned to a normoxic 
environment in RPMI-1640 under the standard 
cell incubator containing 5% CO2, 95% air 
balance, and 98% humidity at 37 °C for 24 h. 
Analysis of neuronal cell viability
For quantitative measurement of neuronal 
viability, 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay 
was added at a final concentration of 0.5 mg/
mL for 4 h as previously described by (28). 
After the cell incubation with MTT, the 
insoluble formazan crystals in the living cells 
was dissolved in 200 μL DMSO for 15 min. The 
optical density (OD) was measured at 570 nm 
with Dynex MMX microplate reader (Dynex, 
Richfield, MN, USA). Survival of the control 
group was defined as 100%. OGD control 
group: the plates exposed to OGD conditions 
without addition of any drugs. Control group: 
the plates not exposed to OGD and without 
addition any drugs. BD1047 group: the plates 
exposed to OGD conditions with addition of 
5 µM BD1047 (the selective antagonist of 
sigma-one receptors). BD1047 and noscapine 
group: the plates exposed to OGD conditions 
with addition of 5 µM BD1047 and different 
concentrations of noscapine (0.5-2 µM).
Nitrite analysis
Detecting NO2
– in culture supernatants was 
assessed by using modified Griess reaction 
(Sigma Chemical Co. St. Louis, MO, USA). 
The Griess reagent system is based on the 
chemical reaction which reacts with sulfanilic 
acid to produce the diazonium ion. A Nitrite 
Standard reference curve must be prepared for 
each assay for accurate quantitation of NO2– 
levels in experimental samples.
After 24 h OGD, the medium in each well 
was removed and centrifuged at 10,000 ×g 
for 10 min at 20 °C. Nitrite was determined 
by mixing 100 µL supernatant with an equal 
volume of Griess reagent at room temperature. 
After 10 min, the absorbance at 540 nm was 
determined on a microplate reader.
Measurement of intracellular free calcium
To describe the intracellular calcium 
levels during ischemia, 4 mM NaN3 (Sigma-
Aldrich, Saint Louis, MS, USA), was used for 
induction of chemical OGD in the presence 
of noscapine with or without BD 1047 and 
continued throughout the entire experiment.
After 30 min chemical OGD, cortical cell 
cultures grown on coverslips were washed 
three times with salt solution containing 
(in mM): 140 NaCl, 3 KCl, 2.5 CaCl2, 1.2 
MgCl2, 7.7 glucose and 10 HEPES, pH 7.4 
and incubated with 4 µM fura 2/AM at room 
temperature for 30 min in a dark incubator.
We used an Olympus IX-71 inverted 
microscope and a cooled charge-couple device 
(CCD) camera equipped with an automated 
fluorescence filter changer for recording and 
subsequent [Ca2+]i calculation. Fluorescence 
emission images of intracellular Fura-2 at 510 
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nm and change its peak excitation from 340 
nm to 380 nm in response to calcium binding. 
Ratio metric analyzes were carried out by 
using ImageJ software.
Statistical analysis
All values were expressed as the mean ± 
standard error mean (SEM). statistical analysis 
of triplicate measurements represented at 
least three independent experiments to obtain 
comparable results for statistical analysis. 
Significant differences among multiple groups 
were examined using One-way analysis of 
variance (ANOVA) followed with Dunnett test. 
Statistical significance was defined as P-values 
less than 0.05 (P < 0.05). the data were analyzed 
using Graph Pad Prism 6.0 software.
Results
 
Involvement of sigma-1 receptors in pro-
tection after OGD/R
To clarify whether the protective effect of 
noscapine against 60 min OGD/R-induced cell 
death was associated with sigma receptors, we 
examined the effects BD1047, the sigma-1 
selective antagonist in the presence or absence 
of different concentrations of noscapine. Cell 
survival following OGD-induced cell damage 
in the presence of BD1047 and different 
concentrations of noscapine was determined.
As shown in Figure 1 the decrease in cell 
viability induced by 5 µM BD1047 (27.05% ± 
0.32) was statistically significant when compared 
to the OGD control group (61.92% ± 1.2).
Our results showed that pretreatment of 
neuronal cells with BD1047 followed by 
noscapine (0.5-2 µmol) after 60 min oxygen–
glucose deprivation/24 h recovery decreased 
cell viability compared with OGD control 
group.
However, although noscapine at its highest 
concentration was unable to exert a complete 
protective effect (compared to OGD/R 
control), it did have a concentration dependent 
protective effect.
Involvement of sigma-1 receptors in 
changing NO production after OGD/R
We examined the effects of 5 µM BD1047 
 
Figure 1. The effect of 5 µM BD1047 in the presence of different concentrations of noscapine 
on primary cultured murine cortical neurons subjected to 60 min oxygen-glucose deprivation/24 
h recovery-induced cell injury. Cell viability was determined using MTT assay. The values are 
presented as the mean ± SEM. ***P < 0.001 vs. BD1047 group. 
  
Figure 1. The effect of 5 µM BD1047 in the presence of different 
concentrations of noscapine on primary cultured murine cortical neurons 
subjected to 60 min oxygen-glucose deprivation/24 h recovery-induced 
cell injury. Cell viability was determined using MTT assay. The values are 
presented as the mean ± SEM. ***P < 0.001 vs. BD1047 group.
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on NO production in primary cortical neurons 
exposed to 30 min OGD/R in the presence 
of different concentrations of noscapine. 
As shown in Figure 2, the pre-treatment of 
neuronal cells with BD1047 (1.70 ± 0.03) after 
30 min OGD/R, produced significantly more 
nitrite compared to OGD control group (1.11 ± 
0.04). Pre-treating neurons with BD1047 and 
noscapine (0.5-2 µM) together after 30 min 
OGD/R induced a decrease in NO production 
as compared with BD1047 alone. The effects 
of noscapine in the presence of BD1047 on 
NO production were concentration dependent; 
however even at the highest noscapine 
concentration the nitrite levels did not return 
to OGD/R control group levels.
The effects of L-NAME (100 µM) on 
NO production were also examined. The 
results indicated that NO production induced 
by 30 min of oxygen– glucose deprivation 
was reduced by L-NAME, a NOS inhibitor 
(Figure 2).
Involvement of sigma-1 receptors in 
modulating intracellular calcium levels after 
OGD/R
Four millimolar NaN3 was able to induce 
a significant increase in [Ca2+]i levels in 
cortical neurons bathed in Ca2+-containing 
medium (146.49% ± 1.75) (Figures 3A-3B). 
Exposure of cortical neurons to NaN3 and 2 
µM noscapine after 30 min, decreased [Ca2+]
i levels by 127.73% ± 1.75. However, the 
chemical OGD-evoked increase in [Ca2+]i 
levels was by 204.98 ± 2.04 in the presence 
of 5 µM BD1047. Nevertheless, when 2 µM 
noscapine was used in the presence of 5 µM 
BD1047 after 30 min, the level of intracellular 
of calcium declined (185.15% ± 31.48) 
(Figures 4A-4B).
 
Figure 2. The effect of 5 µM BD1047 on NO production in the presence of different 
concentrations of noscapine on murine primary cultured cortical neurons during 30 min oxygen-
glucose deprivation/24 h recovery-induced cell injury. The values are presented as the mean ± 
SEM. *P < 0.05, ***P < 0.001 vs. BD1047 group. 
  
Figure 2. The effect of 5 µM BD1047 on NO production in the presence of different 
concentrations of noscapine on murine primary cultured cortical neurons during 30 
min oxygen-glucose deprivation/24 h recovery-induced cell injury. The values are 
presented as the mean ± SEM. *P < 0.05, ***P < 0.001 vs. BD1047 group.
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  Figure 3. Changes in [Ca2+]i levels induced by chemical OGD (4 mM NaN3) in the presence of 2 µM noscapine in 
primary cortical neurons. (A) Time course of NaN3-induced [Ca
2+]i rise in presence of 2 µM noscapine. NaN3 (4 
mM) stimulated [Ca2+]i levels increase. After 30 min ischemic insult, the cells were treated with 2 µM noscapine 
during chemical ischemia. Two micromolar noscapine could decrease [Ca2+]i levels during chemical ischemia. 
(B) Bar graph of mean change in [Ca2+]i levels acquired in response to chemical ischemia in presence of 2 µM 
noscapine. ***P < 0.001 vs. NaN3 group.
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(A) 
 
 (B)  
 
 Figure 4. Changes in [Ca2+]i levels induced by chemical OGD (4 mM NaN3) in the presence of BD1047 
with or without 2 µM noscapine in primary cortical neurons. (A) Time course of NaN3-induced [Ca
2+]i rise 
in presence and absence of 2 µM noscapine and 5 µM BD1047. NaN3 (4 mM) stimulated [Ca
2+]i levels 
increase. After 30 min ischemic insult, the cells treated with 5 µM BD1047. BD1047 could rise [Ca2+]
i levels during chemical ischemia. Two micromolar noscapine added to 5 µM BD1047 during ischemia 
and reduced the [Ca2+]i levels compare to BD1047 alone. (B) Bar graph of mean change in [Ca2+]i levels 
acquired in response to chemical ischemia in presence and absence of 2 µM noscapine and 5 µM BD1047. 
***P < 0.001 vs. NaN3 group.
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Discussion
Research by other workers has demonstrated 
that glutamate is a key neurotransmitter in 
the ischemia induced excitotoxicity process. 
An excess of glutamate is thought to play 
an important role in the progress of cerebral 
infarction via NMDA receptor activation that 
leads to intracellular calcium overload which 
causes in turn toxic reaction and ultimately 
leads to cell damage and death (29–31). 
Although blocking these receptors could help 
to attenuate neuronal damage, inhibition of 
other positive effects of NMDA receptors 
put a limit on usefulness of this treatment. 
Therefore, other strategies had to be used 
to treat hypoxic-ischemic brain damage for 
moderating NMDA receptor function or 
interaction in the cascade of toxic reactions 
that led to excitotoxicity. 
According to the previous investigations, 
sigma receptors could act as putative 
therapeutic targets for reduction of excitotoxic 
and neurodegenerative damage (29, 32). 
Sigma receptors are important because they 
can greatly affect function of glutamate 
receptors during excitotoxicity (33). Ligands 
of both types of sigma receptor subtypes 
possibly synergistic influenced by several 
aspects of neurodegeneration and made it 
possible to modulator effect on neuronal 
degeneration process far more than traditional 
drugs (29). More recently a greater role has 
been attributed to the sigma-1 receptor subtype 
in some pathological and physiological 
processes (2). Sigma-1 receptors are located 
mostly on the endoplasmic reticulum (ER), 
but when cells are exposed to prolonged stress 
or their sigma- one agonists, these receptors 
could translocate to the plasma membrane 
and modulate different ion channels activities 
such as voltage-gated and ligand-gated Ca2+, 
K+, Na+ and Cl- (34). Therefore, based on 
these observations it has been suggested that 
sigma-1 receptor ligands hold promise as 
protective agents for the treatment of cerebral 
ischemia (34–36). 
Many studies have shown that sigma 
receptor ligands have a wide variety of actions 
including protecting of neuronal cells and 
treatment of cerebral ischemia in several cells 
such as retinal ganglion cells, cerebral cortex, 
primary neuronal cultures, and cells used in 
ischemic stroke models (29, 33–35 and 37). 
For example, it has been revealed that the 
potent sigma-1 receptor ligand 4-phenyl-1-
(4-phenylbutyl) piperidine (PPBP) attenuated 
neuronal injury of primary cortical neuronal 
cultures when exposed to 120 min OGD 
or 100 µM glutamate (37). Yang et al. (35) 
have demonstrated that therapeutic use of 
sigma-1 receptor ligand PPBP protected 
striatal neurons in newborn piglets model 
of neonatal global hypoxia-ischemia devoid 
of showing adverse effects associated with 
completely blocking NMDA receptors in the 
developing brain. Similarly, PPBP used in an 
in-vitro model of hypoxia/hypoglycemia in rat 
primary neuronal cultures and could decrease 
neurotoxicity caused by cerebral ischemia 
(32). However, the exact mechanism of this 
effect is unclear.
In previous studies it has been shown that 
noscapine could induce the protective effects 
in variety of ischemic conditions. Khanmoradi 
et al. (23) showed that noscapine exerted 
renoprotective effects via down regulation 
of the inflammatory mediators such as tumor 
necrosis factor-α (TNF-α) and monocyte 
chemoattractant protein1 (MCP-1) in renal 
ischemia–recovery injury in rat models. 
Mahmoudian et al. (22) demonstrated that 
noscapine as a bradykinin antagonist reduced 
inflammation in a rat model of prenatal 
hypoxic-ischemic brain edema. Vahabzadeh et 
al. (24) showed that noscapine decreased NO 
levels and modulation intracellular calcium 
levels in primary murine fetal cortical. Kamei 
et al. (38) showed that the antitussive effect 
of noscapine was dose dependently reduced 
by pre-treatment with rimcazole, a specific 
antagonist of sigma sites in mice. This is 
appearing that noscapine has a protective role 
in ischemic conditions. Therefore, it could be 
postulated that this protective effect afforded 
by noscapine were to some extent dependent 
upon its action on sigma-one receptors. 
As such, the aim of this research is to 
investigate the effects of noscapine in the 
presence of 5 µM BD1047, a sigma-1 receptor 
antagonist in primary cortical culture on 60 
min oxygen-glucose deprivation/24 h recovery 
and show that if different concentrations of 
noscapine could protect neuronal cells against 
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sigma-1 antagonist in this condition and which 
mechanisms were involved.
Lack of oxygen and/or glucose is the main 
reason for ischemic brain injury (39–41). Thus, 
models have been developed to simulate, in-
vitro conditions of low or no oxygen/glucose 
to mimic the pathologic process of ischemic 
stroke (42,43).
 Goldberg and Choi (44) subjected primary 
neuronal cultures to no oxygen/ no glucose 
conditions followed by normal oxygen and 
glucose exposure. He provided evidence that 
this model in-vitro produced cell damage 
similar to neurodegeneration that occurs in 
cerebral ischemic events in man. Therefore, 
the Goldberg OGD/R model was adopted in 
the present work.
MTT assay is widely used to measure cell 
viability and is a good indicator of cellular 
metabolic activity (45). In this experiment 
we used MTT assay to measure the number 
of living cells and were able to show that 5 
µM BD1047 did not have neuroprotective 
effects on primary cortical culture after 60 min 
OGD, when used alone. However, when cells 
incubated in 0.5-2 µM noscapine together 
with 5 µM BD1047 after 60 min OGD/R, 
the neuroprotective effects of noscapine 
were increased in a dose-dependent manner 
compared to BD1047alone but this effect was 
not complete.
It can be concluded that the neuroprotective 
effect of noscapine was at least, partially 
reversed by pretreating cells with BD1047, 
a selective sigma-1 antagonist. This suggests 
that activation of sigma-1 receptors is probably 
involved in the neuroprotective effects of 
noscapine against OGD-induced cell injury.
During the period of oxygen and/or glucose 
deprivation, or in the process of nerve damage, 
amounts of cellular and neuronal energy is 
diminished; this change results in increase 
in glutamate and aspartate concentration. 
Thus, NMDA receptor stimulation, followed 
by intracellular Ca2+ change and Ca2+-CaM 
pathway activation ensue. It is known that 
excessive calcium in neuron and endothelial 
cells can activate the Ca2+-dependent enzyme 
cascades such as neuronal and endothelial 
isoforms of NOS (nNOS and eNOS). 
Therefore, increased intracellular NO levels 
after OGD/R, is expected. (30, 46 and 47). 
In the target cells, NO is converted to the 
cytotoxic molecule peroxynitrite which causes 
damage to DNA and therefore leads to cell 
injury or death (30, 46). In several in-vitro and 
in-vivo animal ischemic models, neurotoxicity 
of NO has been demonstrated. It is also known 
that under certain pathological conditions, NO 
production increases e.g. during ischemia. 
This can lead to cell injury and apoptotic cells 
death by induction of glutamate (11, 35, 46 
and 47).
In this work, we were able to show that 
OGD/R caused an increase in the amount of 
intracellular NO. Also, our data show that 
BD1047 enhanced the NO generation due to 
OGD/R treat. In addition, noscapine was able 
to partially restore NO levels in the presence 
of BD1047. 
Many studies have demonstrated that in the 
presence of ischemia, the generation of NO 
increases (11, 30, 35, 41 and 48). For example, 
Goyagi et al. (11) showed that PPBP, the potent 
sigma-1 agonist, had neuroprotective effects 
and decreased NO production after in-vivo 
striatal tissue damage due to 90 min middle 
cerebral artery occlusion (MCAO) in Wistar 
rats. Also, these effects of PPBP disappeared 
when nNOS was absent or was inhibited. In 
another research, Yang et al. (35) demonstrated 
that in striatal neurons of newborn piglets 
exposed to global hypoxia-ischemia, PPBP 
protected neurons by inhibiting NOS activity 
that was linked to the decreased coupling of 
nNOS to postsynaptic density-95 (PSD-95). 
Therefore, the data obtained in this work 
is consistent with other investigations in so 
far as it shows the importance of sigma-one 
receptors in lowering the NO induced by 
OGD/R treatment. In addition, we were able to 
show that NO-attenuating effects of noscapine 
were also dependent, at least partially, on 
sigma-one receptor function. 
Change in intracellular calcium ion 
concentration induced by ischemic condition, 
result to cell death. Increasing intracellular 
calcium via stimulation of calcium-sensitive 
ion channels led to disestablishment of plasma 
membrane function and finally boosted 
processes such as proteolysis, lipolysis, and 
the production of reactive oxygen species 
that caused cell injury and death (3). In this 
regard, one important mechanism by which 
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sigma-1 receptor ligands protected the 
neuronal cells in glutamate receptor-mediated 
excitotoxicity, was modulating intracellular 
calcium homeostasis and inhibiting ion 
channel function (2, 3 and 9). For example; it 
has been shown that in neurocortical culture 
which was exposed to ischemia, activation 
of sigma-1 receptors protects the neuronal 
cells by decreasing in intracellular calcium 
concentrations (3).
Sodium azide/glucose deprivation model 
(chemical OGD) has been demonstrated 
to provoke electrophysiological and 
neurochemical changes similar to what 
is observed in the OGD model and could 
simulate ischemic conditions. This model 
is preferable to OGD because of producing 
neurochemical changes more rapidly and 
reproducibly, therefore making it easier to 
record the events that are related to changes in 
[Ca2+]i (49). Thus, in this study, sodium azide/
glucose deprivation model was used. Our 
results showed that at the time of chemical 
OGD, the [Ca2+]i was significantly increased 
compared to the external control condition. 
This result is consistent with previous reports, 
which showed that sodium azide could increase 
neuronal [Ca2+]i, to reduced energy production 
(3, 49). So, we examined the [Ca2+]i level in 
neuronal cells exposed to 2 µM noscapine after 
30 min of sodium azide and glucose deprivation 
treatment by using the Ca+2-indicator Fura-
2. The results suggested that exposure to 2 
µM noscapine was able to reverse the effects 
of chemical OGD on intracellular Ca2+ levels 
in primary cortical culture. This study also 
showed that increase in intracellular calcium 
by 5 µM BD1047, sigma-1 receptor antagonist, 
was diminished by noscapine, suggesting that 
noscapine acted as a sigma-1 receptor agonist. 
Our results support previous observations in 
other tissues that sigma-1 receptor ligands could 
modify intracellular calcium ion concentration. 
Katnik et al. (3) demonstrated that 1,3-di-
o-tolyl- guanidine (DTG), a sigma receptor 
agonist, was able to decrease [Ca2+]i elevations 
in cultured cortical neurons from the embryonic 
rats exposed to chemical OGD. Also when the 
cells were treated with BD1047, DTG was not 
able to prevent ischemia induced increases in 
[Ca2+]i. Mueller et al. (34) showed that sigma-1 
receptors exert neuroprotective effects on retinal 
ganglionic cells by suppression of calcium 
signaling through L-type VGCCs. Hayashi et 
al. (50) also showed that in a neuroblastoma-
glioma cell line (NG108), sigma-1 receptors 
modulated calcium signaling. Our data in 
the line with these works, demonstrate that 
noscapine has a protective effect on primary 
cortical culture exposed to sodium azide 
and glucose deprivation via reduction of 
intracellular Ca2+ levels thorough sigma-1 
receptors. Thus, the role of sigma-1 receptor 
activation by noscapine was confirmed from 
the antagonism observed by BD1047.
Conclusion
In conclusion, our data suggests that at least 
some of the neuroprotective effects of noscapine 
are due to its agonistic action on the sigma-1 
receptor and that neuroprotective effects of 
noscapine against ischemia involve sigma-1 
receptor activations induced suppression of 
intracellular NO levels and calcium.
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